$707 Million is the total value of Column Group LLC's 5 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 16.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NGM | NGM Biopharmaceuticals Inc | $303,611,000 | -32.2% | 15,396,116 | 0.0% | 42.97% | +0.2% | |
RAPT | RAPT Therapeutics Inc | $123,526,000 | +43.2% | 3,885,679 | 0.0% | 17.48% | +111.5% | |
RVMD | Sell | Revolution Medicines Inc | $106,242,000 | -35.3% | 3,347,245 | -6.5% | 15.04% | -4.4% |
CNST | Constellation Pharmaceuticals Inc. | $88,780,000 | +44.5% | 2,626,631 | 0.0% | 12.57% | +113.5% | |
ORIC | ORIC Pharmaceuticals Inc. | $84,349,000 | -27.8% | 4,768,181 | 0.0% | 11.94% | +6.7% | |
NRIX | Exit | Nurix Therapeutics Inc | $0 | – | -5,383,333 | -100.0% | -16.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NGM Biopharmaceuticals Inc | 12 | Q3 2023 | 52.5% |
Revolution Medicines Inc | 12 | Q3 2023 | 36.3% |
RAPT Therapeutics Inc | 12 | Q3 2023 | 29.6% |
ORIC Pharmaceuticals Inc. | 12 | Q3 2023 | 14.6% |
Tenaya Therapeutics, Inc. | 9 | Q3 2023 | 24.2% |
Surrozen, Inc. | 9 | Q3 2023 | 8.2% |
eFFECTOR Therapeutics Inc | 9 | Q3 2023 | 6.9% |
Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 12.6% |
Nurix Therapeutics Inc | 2 | Q1 2021 | 16.1% |
Gritstone Oncology Inc | 1 | Q4 2020 | 0.3% |
View Column Group LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-13 |
13F-HR | 2023-07-24 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-12 |
4 | 2022-05-27 |
4 | 2022-05-25 |
13F-HR | 2022-05-16 |
View Column Group LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.